Halozyme Therapeutics and Takeda Pharmaceutical Company have entered into a global collaboration and exclusive license agreement that will apply Halozyme’s ENHANZE® drug‑delivery technology to Takeda’s anti‑integrin biologic vedolizumab, sold under the brand name ENTYVIO. The partnership will enable a subcutaneous formulation of vedolizumab, a treatment currently administered intravenously, by leveraging Halozyme’s recombinant human hyaluronidase PH20 enzyme to expand the drug’s delivery options.
Under the terms of the agreement, Takeda will provide Halozyme with an upfront payment and a series of milestone payments that will be triggered by regulatory approvals, commercial milestones, and sales thresholds. In return, Halozyme will earn low‑to‑mid single‑digit royalties on sales of any vedolizumab product that incorporates ENHANZE®. While the exact figures are not disclosed, the structure is designed to generate a recurring royalty stream that aligns Halozyme’s interests with Takeda’s commercial success in the IBD market.
The deal represents a strategic expansion for Halozyme, adding a high‑profile partner in a large therapeutic area and reinforcing the versatility of its ENHANZE® platform. Halozyme’s guidance for 2025 already reflects a strong revenue trajectory, and the new partnership is expected to contribute to long‑term growth by adding a new royalty source and validating the technology in a disease area with significant unmet patient needs. The collaboration also positions Halozyme to pursue additional subcutaneous opportunities in other biologic classes.
For Takeda, the collaboration addresses a key market challenge: vedolizumab’s upcoming patent expirations in Europe (2027) and the United States (2028). By developing a subcutaneous formulation, Takeda can improve patient convenience, reduce infusion‑center costs, and strengthen its competitive position against emerging biosimilars. The partnership also aligns with Takeda’s broader strategy to advance its gastrointestinal and inflammation portfolio through innovative delivery solutions.
Management comments underscore the strategic fit. Halozyme CEO Dr. Helen Torley said the collaboration “reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas.” Takeda’s head of GI and inflammation, Dr. Robert Hollowell, noted that the partnership “offers a flexible treatment option that matches evolving needs in disease management and could enable vedolizumab to benefit even more patients worldwide.” The announcement is expected to reinforce investor confidence in both companies’ growth prospects.
Overall, the Halozyme–Takeda collaboration is a material event that expands Halozyme’s technology footprint, provides a new revenue stream, and strengthens Takeda’s IBD portfolio ahead of patent expirations. The partnership is likely to influence long‑term financial models for both companies and signals a continued focus on patient‑centric delivery solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.